Roles
- Professor of Radiation Oncology
-
Biography
Dr. Alan Dal Pra is a Professor and Director of Clinical Research in the Department of Radiation Oncology at the University of Miami Miller School of Medicine. He also serves as Medical Director of Radiation Oncology at Sylvester at Coral Gables, The Lennar Foundation Medical Center.
Dr. Dal Pra obtained his Medical Degree from the Federal University of Rio Grande do Sul and underwent Radiation Oncology specialty training in Brazil and Canada. He has postdoctoral training and fellowship in Genitourinary Oncology at McGill University and at the Princess Margaret Cancer Centre, University of Toronto, where he completed training in Genitourinary Translational Oncology at Bristow Lab.
Before joining the University of Miami faculty, Dr. Dal Pra worked in Switzerland as a senior consultant and investigator. He is the principal investigator of a European multicenter trial and investigator or co-investigator of several prospective studies. He is the recipient of many research grants and has authored or co-authored articles appearing in Nature, Nature Genetics, European Urology, Lancet Oncology, Clinical Cancer Research, Red Journal, and other peer-reviewed journals. He serves as an ad-hoc reviewer for several high-profile journals. Dal Pra’s clinical specialties include genitourinary cancers (prostate, bladder, kidney, renal, urinary tract, and penile). He works closely with different multidisciplinary teams at Sylvester to provide the most compassionate and patient-centered care. -
Education & Training
Education
Post Graduate Training
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Sylvester Comprehensive Cancer Center Showcases Radiation Oncology Leadership and Research at ASTRO 2026
Sylvester Leads in Prostate Cancer Research and Treatment
Part of a Global Panel, Sylvester Radiation Oncologist Helps Refine Prostate Cancer Treatment
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 6 clinical trials.
-
Bladder-intact event-free survival (BI-EFS) [Time Frame: Up to 5 years] Defined as histologically proven presence of muscle invasive bladder cancer (MIBC), radiographic evidence of nodal or metastatic disease, performance of radical cystectomy, or death from any cause. Time to event will be calculated from the date of randomization. BI-EFS will be estimated in the two treatment groups using the Kaplan-Meier method and the hazard ratio between ultra-hypofractionation and hypofractionation estimated by fitting a Cox proportional hazards regression model, including a treatment arm indicator variable and adjusting for the three stratification factors employed in the randomization.
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: Phase III
- Enrollment Status: Open
-
A Pilot Study Using a Digital Behavioral Intervention With a Smart Water Bottle to Improve Bladder Filling Compliance in Prostate Cancer Patients Undergoing Radiation Therapy
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Not Accepting
-
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
Compare metastasis-free survival (MFS) of salvage radiation therapy (RT) and gonadotropin releasing hormone (GnRH) agonist/antagonist versus (vs.) RT/GnRH agonist/antagonist with apalutamide for patients with pathologic node-positive prostate cancer after radical prostatectomy with detectable prostate-specific antigen (PSA).
- Principal Investigator: Alan Libardi Dal Pra
- Study Phase: Phase III
- Enrollment Status: Not Accepting